Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Diffuse Large B Cell Lymphoma, Disease Patterns, Treatment Paradigms and Clinical Outcomes. a Single Center Study from United Arab Emirates (UAE)

Arif Alam, Nida Alam, Khaled Al Qawasmeh, Philip L. McCarthy

Blood (2024) 144 (Supplement 1): 6445.

https://doi.org/10.1182/blood-2024-199186

Published: 2024

Journal Articles

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Rahul Banerjee, Amber R. Fritz, Othman S. Akhtar, Ciara Louise Freeman, Andrew J. Cowan, Nina Shah, Heather J. Landau, Shaji Kumar, Dan T. Vogl, Yvonne A. Efebera, Philip L. McCarthy, David H. Vesole, Adam Mendizabal, Amrita Y Krishnan, George Somlo, Edward A. Stadtmauer, Marcelo C. Pasquini

Blood (2024) 144 (Supplement 1): 81.

https://doi.org/10.1182/blood-2024-199615

Published: 2024

Journal Articles

Cytoreductive Paradigms for Hyperleukocytosis in Acute Leukemia (AL) Using Venetoclax based Regimen. Single Center Experience from United Arab Emirates

Arif Alam, Nida Alam, Khaled Al Qawasmeh, Philip L. McCarthy

Blood (2024) 144 (Supplement 1): 5950.

https://doi.org/10.1182/blood-2024-206102

Published: 2024

Journal Articles

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Blood (2024) 144 (Supplement 1): 3289.

https://doi.org/10.1182/blood-2024-211352

Published: 2024

Journal Articles

Patterns of Disease, Risk Factors and Treatment in Chronic Lymphocytic Leukemia (CLL). a retrospective Report of Real World Patient Cohort from United Arab Emirates

Arif Alam, Khaled Al Qawasmeh, Nida Alam, Philip L. McCarthy

Blood (2023) 142 (Supplement 1): 6558.

https://doi.org/10.1182/blood-2023-182574

Published: 2023

Journal Articles

Disease Control Affects Outcomes of Patients with Relapsed Diffuse Large B Cell Lymphoma Treated with CD19 Directed CAR T-Cell Therapy

Dorothy C Pan, Showkat Hamid, Megan Herr, Kristopher Attwood, Philip L. McCarthy, Maureen Ross, Grant Schofield, Matthew J Cortese, Dominick Lamonica, Jerry Thwin Wong, Kai Fu, Peter Maslak, Marco Davila, Renier Brentjens, Francisco J. Hernandez-Ilizaliturri

Blood (2023) 142 (Supplement 1): 7376.

https://doi.org/10.1182/blood-2023-187631

Published: 2023

Journal Articles

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2023) 142 (Supplement 1): 4762.

https://doi.org/10.1182/blood-2023-181032

Published: 2023

Journal Articles

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Blood (2022) 140 (Supplement 1): 4472–4474.

https://doi.org/10.1182/blood-2022-167018

Published: 2022

Journal Articles

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Peter Westervelt, Partow Kebriaei, Mark Juckett, Andrew S. Artz, Onyee Chan, Philip L. McCarthy, Sherif S Farag, Anurag K. Singh, Eytan Stein, Jeffrey Humphrey, William Baeder, Ji Hyun Lee, Alison Occhiuti, Jeanie Tang, David Santos, Kirk Bertelsen, Balaji Mahender, Nicole Henry, Shawn Rose

Blood (2022) 140 (Supplement 1): 2117–2119.

https://doi.org/10.1182/blood-2022-162406

Published: 2022

Journal Articles

Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

Yiwen Wang, Junke Wang, Ezgi Karaesmen, Abbas A. Rizvi, Alyssa I. Clay-Gilmour, Qianqian Zhu, Loreall Pooler, Xin Sheng, Christopher A. Haiman, Amy Webb, Guy Brock, Stephen R. Spellman, Philip L. McCarthy, Marcelo C Pasquini, Theresa E. Hahn, Lara E. Sucheston-Campbell

Blood (2022) 140 (Supplement 1): 10611–10612.

https://doi.org/10.1182/blood-2022-158870

Published: 2022

Journal Articles

β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies

Saeed Daneshmandi, Cameron R. MacDonald, Manu Pandey, Jee Eun Choi, Nathan Roberts, Suzanne M Hess, Teresa W.M. Fan, Richard M. Higashi, Andrew N. Lane, Prashant Singh, Jianmin Wang, Philip L. McCarthy, Elizabeth A. Repasky, Hemn Mohammadpour

Blood (2022) 140 (Supplement 1): 8867–8869.

https://doi.org/10.1182/blood-2022-167654

Published: 2022

Journal Articles

Low Intensity Salvage Therapy after Failure of Standard (7 +3) Induction Regimen in Acute Myeloid Leukemia (AML). a Single Center Experience from United Arab Emirates

Arif Alam, Khaled al Qawasmeh, Philip L. McCarthy

Blood (2022) 140 (Supplement 1): 11705–11706.

https://doi.org/10.1182/blood-2022-156359

Published: 2022

Journal Articles

A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders

Alankrita Taneja, Katy Wang, Sarah Parker, Sheeba Ba Aqeel, Joseph D. Tario, Jr., Hassan Awada, Arya Roy, Maximilian Merz, Philip L. McCarthy, Jens Hillengass

Blood (2022) 140 (Supplement 1): 10029–10030.

https://doi.org/10.1182/blood-2022-169163

Published: 2022

Journal Articles

Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience

Sheeba Ba Aqeel, Alankrita Taneja, Adrienne Groman, Sarah Parker, Karan Jatwani, Arya Mariam Roy, Kristopher Attwood, Philip L. McCarthy, Jens Hillengass

Blood (2022) 140 (Supplement 1): 13216–13217.

https://doi.org/10.1182/blood-2022-165549

Published: 2022

Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Blood (2022) 140 (Supplement 1): 4834–4838.

https://doi.org/10.1182/blood-2022-162741

Published: 2022

Journal Articles

Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Othmane Jadi, Hancong Tang, Kelly Shea Olsen, Steven Vensko, Qianqian Zhu, Yiwen Wang, Christopher A. Haiman, Loreall Pooler, Xin Sheng, Guy Brock, Amy Webb, Marcelo C Pasquini, Philip L. McCarthy, Stephen R. Spellman, Theresa E. Hahn, Benjamin G. Vincent, Paul M. Armistead, Lara E. Sucheston-Campbell

Blood (2022) 140 (Supplement 1): 668–670.

https://doi.org/10.1182/blood-2022-167165

Published: 2022

Journal Articles

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Luciano J. Costa, Shaji K Kumar, Shebli Atrash, Michaela Liedtke, Gurbakhash Kaur, Benjamin A. Derman, P. Leif Bergsagel, Sham Mailankody, Philip L. McCarthy, Josiana Limones, Yanping Chen, Sharmila Das, Jerill Thorpe, Jonathan Cacciatore, Garnet Navarro, Ashley K Koegel, Michael R. Burgess, Kristen Hege, Shambavi Richard

Blood (2022) 140 (Supplement 1): 1360–1362.

https://doi.org/10.1182/blood-2022-160038

Published: 2022

Journal Articles

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Olalekan O. Oluwole, Saad S. Kenderian, Parveen Shiraz, Reem Karmali, Ran Reshef, Philip L. McCarthy, Nilanjan Ghosh, Aleksandr Lazaryan, Simone Filosto, Soumya Poddar, Daqin Mao, Andrew Peng, Adrian Kilcoyne, Myrna Nahas, Sattva S. Neelapu

Blood (2022) 140 (Supplement 1): 10318–10320.

https://doi.org/10.1182/blood-2022-167688

Published: 2022

Journal Articles

Galectin-3 Signaling in Donor T Cells Regulates Acute Graft Versus Host Disease (aGvHD) after Allogenic Transplantation

Hemn Mohammadpour, Takemasa Tsuji, Cameron R. MacDonald, Joseph L. Sarow, Jingxin Qiu, Junko Matsuzaki, Kristopher Attwood, Bruce R. Blazar, Kunle Odunsi, Elizabeth A. Repasky, Philip L. McCarthy

Blood (2021) 138 (Supplement 1): 2765.

https://doi.org/10.1182/blood-2021-150777

Published: 2021

Journal Articles

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Blood (2021) 138 (Supplement 1): 899.

https://doi.org/10.1182/blood-2021-149659

Published: 2021

NARROW

Diffuse Large B Cell Lymphoma, Disease Patterns, Treatment Paradigms and Clinical Outcomes. a Single Center Study from United Arab Emirates (UAE)

24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702

Cytoreductive Paradigms for Hyperleukocytosis in Acute Leukemia (AL) Using Venetoclax based Regimen. Single Center Experience from United Arab Emirates

Uncovering the Tumor Antigen Landscape in Patients Undergoing Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance Treatment

Patterns of Disease, Risk Factors and Treatment in Chronic Lymphocytic Leukemia (CLL). a retrospective Report of Real World Patient Cohort from United Arab Emirates

Disease Control Affects Outcomes of Patients with Relapsed Diffuse Large B Cell Lymphoma Treated with CD19 Directed CAR T-Cell Therapy

Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies

Low Intensity Salvage Therapy after Failure of Standard (7 +3) Induction Regimen in Acute Myeloid Leukemia (AML). a Single Center Experience from United Arab Emirates

A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders

Real-World Clinical Outcomes of Multiple Myeloma Patients with High-Risk Cytogenetics Treated with Dararvd, Single Center Experience

Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

ZUMA-19: A Phase 1/2 Study of Axicabtagene Ciloleucel Plus Lenzilumab in Patients With Relapsed or Refractory Large B-Cell Lymphoma

Galectin-3 Signaling in Donor T Cells Regulates Acute Graft Versus Host Disease (aGvHD) after Allogenic Transplantation

Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed By Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only